Roche Holding Ltd (SIX: ROG): Corporate Profile & Financials
Source: Roche Holding Ltd Annual Report 2025
Roche Holding Ltd is a global healthcare pioneer operating through two core divisions: Pharmaceuticals and Diagnostics. The Group discovers, develops, manufactures, and distributes innovative medicines and integrated laboratory solutions designed to span the complete continuum of care—from early detection and screening to targeted therapy and disease monitoring.
- Pharmaceuticals Sales: Segment revenue: CHF 47.67 B (75.24%).
- Diagnostics Sales: Segment revenue: CHF 13.85 B (21.86%).
- Corporate Sales: Segment revenue: 0.
- Pharmaceuticals Operating Profit: Segment revenue: CHF 21.67 B (34.20%).
- Diagnostics Operating Profit: Segment revenue: CHF 1.07 B (1.69%).
- Corporate Operating Profit: Segment revenue: CHF 4.26 B (6.72%).
📋 Quick Facts / Company Snapshot: Roche Holding (SIX: ROG)
| Attribute | Corporate Disclosure |
|---|---|
| Official Name | Roche Holding Ltd |
| Ticker Symbol & Exchange | ROG / RO (SIX Swiss Exchange), TSE:4519 (Chugai Pharmaceutical Co., Ltd. on Tokyo Stock Exchange) |
| Principal Executive Offices | Grenzacherstrasse 124, 4070 Basel, Switzerland |
| Industry / Sector | Pharmaceuticals & Diagnostics / Healthcare |
| Founded / Incorporated | 1896 |
| Total Employees | 112,774 |
| Chief Executive Officer (CEO) | Thomas Schinecker |
| Chief Financial Officer (CFO) | Alan Hippe |
| Official Website | https://www.roche.com |
| Fiscal Year-End | 31 December |
| Primary Accounting Standard | IFRS Accounting Standards |
| Parent Company | Roche Holding Ltd |
| Chairman of the Board of Directors | Severin Schwan |
| Statutory Auditor | KPMG AG, Basel, Switzerland |
| Number of Issued Shares | 106,691,000 |
| Number of Non-Voting Equity Securities (Genussscheine) | 702,562,700 |
| Principal Subsidiaries | F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co., Ltd., Genentech, Inc., Foundation Medicine, Inc., Spark Therapeutics, Inc., 89bio, Inc., Pentavision Biosciences Ltd, Poseida Therapeutics, Inc. |
| Core Operational Divisions | Pharmaceuticals Division, Diagnostics Division |
| Global Headquarters Location | Basel, Switzerland |
| Global Reporting Currency | Swiss Franc (CHF) |
1. Corporate Identity: Roche Holding Overview & History
The Big Picture
Roche Holding Ltd is a global healthcare pioneer operating through two core divisions: Pharmaceuticals and Diagnostics. The Group discovers, develops, manufactures, and distributes innovative medicines and integrated laboratory solutions designed to span the complete continuum of care—from early detection and screening to targeted therapy and disease monitoring. With its operational footprint anchored in Basel, Switzerland, Roche leverages significant scientific scale across Oncology, Neurology, Immunology, Ophthalmology, and Infectious Diseases, serving healthcare systems, hospitals, and commercial laboratories across the world.
The company operates an integrated healthcare model that combines targeted pharmaceuticals with precision diagnostics, allowing clinicians to tailor medical interventions to the genetic and molecular characteristics of specific patient populations. Through its majority-owned Japanese subsidiary Chugai Pharmaceutical Co., Ltd. and wholly owned biotechnology leaders such as Genentech, Roche maintains an expansive global commercial reach while deploying billions in capital toward novel molecular mechanisms and automated clinical laboratory systems.
The Founders & Their Legacy
The company traces its foundational legacy back more than 125 years to founder Fritz Hoffmann-La Roche, who established the enterprise in 1896 on the principle of manufacturing standardized, industrial-quality healthcare solutions. Over generations, this heritage evolved into modern biotechnology innovation, supported by the ongoing stewardship of the Hoffmann and Oeri founder family pooling syndicate. In 1961, Dr. Lukas (Luc) Hoffmann, grandson of the founder and a former member of the Roche Board of Directors, co-founded the World Wide Fund for Nature (WWF), beginning a multi-decade institutional engagement in global ecological stewardship.
The family pooling agreement, which originated in 1948 and was indefinitely extended in 2009, continues to provide long-term capital stability. This continuity enables the Group to pursue capital-intensive, multi-year scientific endeavours requiring extensive clinical research schedules without the disruptions of short-term market pressures.
The Journey: History & Evolution
Roche’s strategic trajectory over the past quarter-century has been defined by significant structural acquisitions, biological innovation, and global commercial expansion:
- 2001–2002 Alliance with Chugai: Roche completed an alliance that merged Nippon Roche into Chugai Pharmaceutical Co., Ltd., establishing an operating subsidiary listed in Tokyo that provides specialized small-molecule research, antibody engineering, and marketing exclusivity across Japan.
- Integration of Genentech: Full ownership of South San Francisco-based Genentech positioned the Group as a commercial leader in oncology, developing targeted biological therapies including Herceptin, Avastin, and Rituxan.
- Advanced Genomic Platforms: The acquisitions of Foundation Medicine and Flatiron Health expanded Roche’s data assets into comprehensive genomic profiling and real-world oncology clinical data.
- Targeted Cell & Gene Expansion (2024–2025): Recent strategic additions—including LumiraDx and Carmot Therapeutics in 2024, followed by Poseida Therapeutics, Pentavision Biosciences Ltd, and 89bio, Inc. in 2025—strengthened the Group’s presence in allogeneic CAR-T cellular therapy, next-generation ophthalmology antibodies, and metabolic treatments for MASH.
The Corporate Umbrella
Roche Holding Ltd acts as the overarching holding entity for an extensive global corporate network, organizing its operations into the Pharmaceuticals Division, the Diagnostics Division, and Corporate administrative functions. The Group owns operating subsidiaries around the world, managing manufacturing campuses, discovery laboratories, and sales networks across Europe, North America, Latin America, Asia-Pacific, and EMEA.
Under this umbrella, research hubs function with scientific autonomy. Genentech Research and Early Development (gRED), Roche Pharma Research and Early Development (pRED), and Chugai operate alongside specialized diagnostic sites. These efforts are unified by global product development, clinical governance, and regulatory strategies managed from Group headquarters in Basel.
2. The Business Engine: Roche Holding Business Model & Revenue Segments
The Core Divisions
The Group divides its primary business operations into two complementary divisions, complemented by centralized Corporate administrative functions:
| Segment (in CHF millions) | 2025 | 2024 | Latest YoY (%) |
|---|---|---|---|
| Pharmaceuticals Sales | 47,669 | 46,171 | +3.24% |
| Diagnostics Sales | 13,847 | 14,324 | -3.33% |
| Corporate Sales | 0 | 0 | N/M |
| Pharmaceuticals Operating Profit | 21,666 | 15,587 | +39.00% |
| Diagnostics Operating Profit | 1,070 | 1,946 | -45.02% |
| Corporate Operating Profit | (4,260) | (4,116) | +3.50% |
| Group Consolidated Sales | 61,516 | 60,495 | +1.69% |
| Group Consolidated Operating Profit | 18,476 | 13,417 | +37.71% |
The Pharmaceuticals Division is Roche’s primary revenue driver, contributing 77.49% of total Group sales in 2025. It focuses on developing and commercializing prescription therapeutics across oncology, haematology, neurology, immunology, ophthalmology, and cardiometabolic diseases. Core operating profit within Pharmaceuticals grew to CHF 23,440 million, yielding a core operating profit margin of 49.17% of sales.
The Diagnostics Division designs and distributes high-throughput diagnostic platforms, digital workflows, and specialized reagents for central hospitals, commercial laboratories, and decentralized clinical environments. The division generated CHF 13,847 million in sales and delivered an operating profit of CHF 1,070 million, navigating Chinese healthcare pricing reforms while expanding its installed instrument base and rolling out automated mass spectrometry systems.
The Global Product Catalog
Roche’s portfolio of pharmaceutical medicines and automated diagnostic platforms serves medical institutions worldwide. Across the clinical life cycle, the Group maintains 66 new molecular entities in its discovery pipeline, advancing 10 new molecules into phase III clinical trials during 2025.
The commercial therapeutic catalog is supported by key anchor products across major clinical indications:
- Neurology: Led by Ocrevus (for relapsing and primary progressive multiple sclerosis), Evrysdi (oral survival motor neuron-2 splicing modifier for spinal muscular atrophy), and Elevidys (gene therapy for Duchenne muscular dystrophy).
- Haematology & Oncology: Anchored by Hemlibra (bispecific antibody for haemophilia A), Polivy (antibody-drug conjugate for diffuse large B-cell lymphoma), Tecentriq (anti-PD-L1 cancer immunotherapy), Phesgo (subcutaneous fixed-dose combination of Perjeta and Herceptin), Kadcyla, Alecensa, Columvi, and Lunsumio.
- Immunology: Features Xolair (anti-IgE biologic for severe asthma, chronic spontaneous urticaria, and food allergies) and Actemra/RoActemra (anti-IL-6 receptor biologic for rheumatoid arthritis and cytokine release syndrome).
- Ophthalmology: Centered on Vabysmo (bispecific antibody targeting Ang-2 and VEGF-A for neovascular AMD, DME, and RVO) alongside Susvimo ocular implants.
- Diagnostics Customer Areas: The diagnostic catalog is organized into Core Lab (immunoassays, clinical chemistry, custom biotech), Molecular Lab (pathogen detection, donor screening, sexual health, Foundation Medicine genomic testing), Near Patient Care (point-of-care, blood glucose, integrated diabetes management), and Pathology Lab (advanced tissue staining, digital pathology, companion diagnostics).
The Names You Know
Roche’s top pharmaceutical treatments account for a significant share of Group revenues, with established medicines generating substantial international demand:
- Ocrevus (CHF 7,010 million): Roche’s top-selling prescription medicine, expanding globally due to the rollout of its subcutaneous formulation alongside its established intravenous infusion.
- Hemlibra (CHF 4,754 million): A standard of care for haemophilia A with or without factor VIII inhibitors, generating double-digit international sales growth.
- Vabysmo (CHF 4,102 million): An eye-disease therapy for wet age-related macular degeneration and diabetic macular oedema that surpassed CHF 4 billion in annual sales.
- Tecentriq (CHF 3,566 million): A cancer immunotherapy indicated across small cell lung cancer, non-small cell lung cancer, and hepatocellular carcinoma.
- Xolair (CHF 3,075 million): Grew 32% at constant exchange rates following its commercial launch for food allergy indications in the United States.
- Phesgo (CHF 2,441 million): Rapidly converting HER2-positive breast cancer patients from intravenous Perjeta and Herceptin to a single subcutaneous formulation, recording 48% CER revenue expansion.
Mapping the Global Reach
The Group reports sales across major geographical territories based on customer destination. Operating results reflect broad global distribution, led by North America and Europe:
| Geographical Market (in CHF millions) | 2025 Sales | 2024 Sales | Latest YoY (%) |
|---|---|---|---|
| United States | 29,504 | 28,902 | +2.08% |
| Rest of North America | 972 | 889 | +9.34% |
| Germany | 3,122 | 2,928 | +6.63% |
| Switzerland | 819 | 747 | +9.64% |
| Rest of Europe | 10,860 | 10,291 | +5.53% |
| China | 4,815 | 5,422 | -11.20% |
| Japan | 3,035 | 3,154 | -3.77% |
| Rest of Asia | 3,784 | 3,663 | +3.30% |
| Latin America | 3,245 | 3,249 | -0.12% |
| Africa, Australia and Oceania | 1,360 | 1,250 | +8.80% |
| Total Consolidated Group Sales | 61,516 | 60,495 | +1.69% |
The United States remains Roche’s largest commercial market, accounting for 47.96% of global revenues in 2025. In the US, three national wholesale distributors—McKesson Corp. (CHF 9 billion), Cencora, Inc. (CHF 7 billion), and Cardinal Health, Inc. (CHF 4 billion)—represented approximately one-third of total consolidated Group sales, with 99% of these volumes distributed through the Pharmaceuticals Division.
European sales expanded to CHF 14,801 million, supported by demand for subcutaneous Ocrevus and Phesgo, and broader access for Vabysmo. In Asia, sales reached CHF 11,634 million, where volume gains in China and Japan were balanced against the pricing impacts of volume-based procurement reforms across Chinese Core Lab diagnostic portfolios.
The Brick & Mortar Footprint
Roche’s physical operating infrastructure encompasses research centers, primary production campuses, administrative centers, and distribution hubs across the world. At 31 December 2025, the Group carried property, plant, and equipment with a consolidated balance sheet net book value of CHF 21,949 million, alongside right-of-use leased assets valued at CHF 985 million.
Key operational and capital assets include:
- Basel and Kaiseraugst, Switzerland: Group corporate headquarters, global informatics, pharmaceutical development, and the construction site of Building 12, a CHF 500 million research and development center initiated in late 2025.
- South San Francisco, California: Genentech headquarters and biotechnology production campus, which underwent boiler efficiency upgrades and facility adjustments following the divestment of the Vacaville site.
- Mannheim and Penzberg, Germany: Diagnostic instrument assembly, biochemical reagent production, and biomanufacturing centers supporting the Core Lab and Pathology Lab customer areas.
- Tokyo and Kamakura, Japan: Pharmaceutical development, research laboratories, and administrative offices operated by Chugai Pharmaceutical Co., Ltd.
- Rotkreuz, Switzerland: International diagnostic instrumentation and assay automation research and development hub.
- Machinery & Operating Lease Placements: Diagnostic instrumentation placed at client hospital and laboratory sites carried a net book value of CHF 1,988 million within operating leases, supporting ongoing reagent sales.
3. The Financial Health: Roche Holding (FY 2025) Audited Financial Statements
Earnings, Expenses & Profits: Roche Holding Income Statement
The Consolidated Income Statement reflects operating revenue growth, efficiency measures in research administration, and comparisons with prior-year impairment charges:
| Line Item (in CHF millions) | 2025 | 2024 | Latest YoY (%) |
|---|---|---|---|
| Sales | 61,516 | 60,495 | +1.69% |
| Other revenue | 1,840 | 1,900 | -3.16% |
| Total Revenue | 63,356 | 62,395 | +1.54% |
| Cost of sales | (16,645) | (16,283) | +2.22% |
| Research and development | (13,352) | (15,304) | -12.75% |
| Selling, general and administration | (15,161) | (14,896) | +1.78% |
| Other operating income (expense) | 278 | (2,495) | N/M |
| Operating profit | 18,476 | 13,417 | +37.71% |
| Financing costs | (1,349) | (1,412) | -4.46% |
| Other financial income (expense) | (154) | (212) | -27.36% |
| Profit before taxes | 16,973 | 11,793 | +43.92% |
| Income taxes | (3,174) | (2,606) | +21.80% |
| Net income | 13,799 | 9,187 | +50.20% |
| Attributable to Roche shareholders | 12,880 | 8,277 | +55.61% |
| Attributable to non-controlling interests | 919 | 910 | +0.99% |
Operating profit for the year rose to CHF 18,476 million, an increase of 37.71% in reported Swiss francs and 48% at constant exchange rates. This operating performance was supported by disciplined research expenditure, which decreased to CHF 13,352 million, alongside a positive swing in other operating income (expense) from a net expense of CHF 2,495 million in 2024 to a net income of CHF 278 million in 2025. The prior-year results included goodwill impairments of CHF 3,209 million related to Flatiron Health and Spark Therapeutics.
Consolidated net income reached CHF 13,799 million, of which CHF 12,880 million was attributable to Roche shareholders. The effective tax rate stood at 18.70%, compared to 22.10% in 2024. Diluted earnings per share increased to CHF 16.04, up from CHF 10.31 in the prior period.
Assets, Debts & Equity: Roche Holding Balance Sheet
The Consolidated Balance Sheet highlights the Group’s non-current asset base, current working capital positions, debt structure, and equity reserves:
| Line Item (in CHF millions) | 31 December 2025 | 31 December 2024 | Latest YoY (%) |
|---|---|---|---|
| Property, plant and equipment | 21,949 | 22,557 | -2.70% |
| Right-of-use assets | 985 | 1,183 | -16.74% |
| Goodwill | 7,492 | 7,876 | -4.88% |
| Intangible assets | 19,321 | 17,303 | +11.66% |
| Deferred tax assets | 8,411 | 8,569 | -1.84% |
| Defined benefit plan assets | 1,791 | 2,256 | -20.61% |
| Other non-current assets | 2,025 | 2,021 | +0.20% |
| Total non-current assets | 61,974 | 61,765 | +0.34% |
| Inventories | 7,479 | 7,606 | -1.67% |
| Accounts receivable | 11,506 | 11,297 | +1.85% |
| Current income tax assets | 393 | 415 | -5.30% |
| Other current assets | 3,875 | 3,401 | +13.94% |
| Marketable securities | 9,894 | 10,342 | -4.33% |
| Cash and cash equivalents | 5,582 | 6,975 | -19.97% |
| Total current assets | 38,729 | 40,036 | -3.26% |
| Total assets | 100,703 | 101,801 | -1.08% |
| Long-term debt | (27,430) | (30,722) | -10.72% |
| Deferred tax liabilities | (884) | (832) | +6.25% |
| Defined benefit plan liabilities | (3,950) | (4,381) | -9.84% |
| Provisions, non-current | (1,055) | (1,079) | -2.22% |
| Other non-current liabilities | (1,503) | (1,603) | -6.24% |
| Total non-current liabilities | (34,822) | (38,617) | -9.83% |
| Short-term debt | (4,206) | (3,932) | +6.97% |
| Current income tax liabilities | (2,867) | (2,923) | -1.92% |
| Provisions, current | (1,743) | (1,726) | +0.98% |
| Accounts payable | (5,779) | (4,894) | +18.08% |
| Other current liabilities | (13,406) | (13,548) | -1.05% |
| Total current liabilities | (28,001) | (27,023) | +3.62% |
| Total liabilities | (62,823) | (65,640) | -4.29% |
| Capital and reserves attributable to Roche shareholders | 33,802 | 31,767 | +6.41% |
| Equity attributable to non-controlling interests | 4,078 | 4,394 | -7.19% |
| Total equity | 37,880 | 36,161 | +4.75% |
| Total liabilities and equity | (100,703) | (101,801) | -1.08% |
Total assets stood at CHF 100,703 million at year-end, supported by a cash, cash equivalents, and marketable securities position of CHF 15,476 million. Goodwill and intangible assets totaled CHF 26,813 million, reflecting the capitalisation of research assets and additions from the Poseida and 89bio transactions.
Total consolidated debt decreased to CHF 31,636 million, from CHF 34,654 million in 2024, due to scheduled bond redemptions and favorable foreign exchange movements on US dollar-denominated liabilities. Total equity grew to CHF 37,880 million, improving the Group’s equity ratio to 37.62% of total assets.
Cash Flow & Capital Allocation: Roche Holding Cash Flow Statement
The Consolidated Statement of Cash Flows details operational cash generation, capital deployment into physical and intangible assets, corporate acquisitions, and financing disbursements:
| Line Item (in CHF millions) | 2025 | 2024 | Latest YoY (%) |
|---|---|---|---|
| Cash generated from operations | 25,524 | 24,332 | +4.90% |
| (Increase) decrease in net working capital | (1,657) | 1,161 | N/M |
| Payments made for defined benefit plans | (654) | (661) | -1.06% |
| Utilisation of provisions | (1,222) | (1,012) | +20.75% |
| Other operating cash flows | 0 | 1 | -100.00% |
| Income taxes paid | (3,139) | (3,727) | -15.78% |
| Total cash flows from operating activities | 18,852 | 20,094 | -6.18% |
| Purchase of property, plant and equipment | (3,748) | (3,529) | +6.21% |
| Purchase of intangible assets | (2,031) | (1,480) | +37.23% |
| Disposal of property, plant and equipment | 139 | 61 | +127.87% |
| Disposal of intangible assets | 2 | 0 | N/M |
| Disposal of products | 43 | 376 | -88.56% |
| Divestment of net assets previously held for sale | 0 | 1,049 | -100.00% |
| Business combinations | (911) | (2,836) | -67.88% |
| Asset acquisitions | (2,167) | (283) | +665.72% |
| Divestment of subsidiaries | 16 | 1 | +1500.00% |
| Interest received and dividends received on marketable securities | 167 | 232 | -28.02% |
| Sales of equity securities and debt securities | 241 | 198 | +21.72% |
| Purchases of equity securities and debt securities | (263) | (112) | +134.82% |
| Sales (purchases) of money market instruments and time accounts, net | 54 | (5,084) | N/M |
| Other investing cash flows | (85) | 14 | N/M |
| Total cash flows from investing activities | (8,543) | (11,393) | -25.02% |
| Proceeds from issue of bonds and notes | 2,299 | 7,915 | -70.95% |
| Redemption and repurchase of bonds and notes | (3,386) | (3,095) | +9.40% |
| Increase (decrease) in commercial paper | 656 | (709) | N/M |
| Increase (decrease) in other debt | 276 | (292) | N/M |
| Hedging and collateral arrangements | (288) | 30 | N/M |
| Interest paid | (1,189) | (1,145) | +3.84% |
| Principal portion of lease liabilities paid | (364) | (350) | +4.00% |
| Dividends paid | (8,385) | (8,043) | +4.25% |
| Equity-settled equity compensation plans, net of own equity transactions | (987) | (1,130) | -12.65% |
| Total cash flows from financing activities | (11,368) | (6,819) | +66.71% |
| Net effect of currency translation on cash and cash equivalents | (334) | (283) | +18.02% |
| Increase (decrease) in cash and cash equivalents | (1,393) | 1,599 | N/M |
| Cash and cash equivalents at 1 January | 6,975 | 5,376 | +29.74% |
| Cash and cash equivalents at 31 December | 5,582 | 6,975 | -19.97% |
Operating cash flow generation reached CHF 18,852 million, lower than the prior year’s CHF 20,094 million due to an inventory and trade working capital build of CHF 1,657 million, alongside income tax cash payments of CHF 3,139 million. Operational cash inflows covered capital expenditures in property, plant, and equipment (CHF 3,748 million) and intangible investments (CHF 2,031 million).
Financing activities saw a net cash outflow of CHF 11,368 million. This included CHF 8,385 million in shareholder and minority dividend distributions, net debt retirements across bond maturities, and share repurchases to satisfy conversion obligations under employee equity compensation programs.
Funding the Future: R&D and Expansion Spending
Research and development expenditure on a core basis was CHF 12,243 million in 2025, representing 19.90% of consolidated Group sales. On a statutory IFRS basis, R&D spending totaled CHF 13,352 million, reflecting lower program closure costs compared to the prior year.
Capital investments in expansion, laboratories, and operational technology included:
- United States Investment Commitment: Announced a multi-year USD 50 billion investment plan across pharmaceutical and diagnostic sectors in the US over the next five years, aimed at expanding research capabilities and manufacturing capacity.
- Additions to Intangibles: Capitalised CHF 2,523 million in intangible assets, with key additions including CHF 1,469 million from the 89bio acquisition for the phase III MASH asset pegozafermin, CHF 331 million for Pentavision ophthalmology antibodies, and CHF 1,117 million from licensing Zealand Pharma’s petrelintide.
- Building 12 (Basel Center): Initiated construction on a CHF 500 million R&D hub at Group headquarters in Basel to advance research across oncological and immunological mechanisms.
- Diagnostic Laboratory Placement: Placed more than 3,400 analytical units in the cobas pure line (+55% installed base growth) and over 6,700 analytical units in the cobas pro line (+52% installed base growth), supporting automated assay volume expansion.
4. The Corporate Family Tree: Roche Holding Subsidiaries & Acquisitions
Subsidiaries, Associates, & Shared Ventures
The consolidated Group structure encompasses fully owned and majority-controlled operational operating subsidiaries across key operating regions:
- Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan): Fully consolidated subsidiary listed on the Tokyo Stock Exchange (TSE:4519). Roche holds a 61.10% controlling equity interest, operating under Basic Alliance and licensing agreements that grant Chugai commercialization rights in Japan and Roche right of first refusal in global territories outside Japan, South Korea, and Taiwan.
- Genentech, Inc. (South San Francisco, United States): Wholly owned biotechnology operating arm responsible for discovery, early-stage oncology, and therapeutic development in North America.
- Foundation Medicine, Inc. (Boston, United States): Wholly owned molecular information operating unit specializing in comprehensive genomic profiling and companion diagnostics.
- Spark Therapeutics, Inc. (Philadelphia, United States): Wholly owned gene therapy center advancing adeno-associated virus investigational vectors for haemophilia A.
- Poseida Therapeutics, Inc. (San Diego, United States): Acquired in 2025 for a net consideration of CHF 1,029 million, advancing allogeneic CAR-T cellular therapy candidates including P-BCMA-ALLO1.
- 89bio, Inc. (South San Francisco, United States): Acquired in October 2025 for an initial cash consideration of USD 2.4 billion, providing rights to pegozafermin for metabolic dysfunction-associated steatohepatitis (MASH).
- Pentavision Biosciences Ltd (United States / Global): Acquired in November 2025 for an initial cash consideration of USD 410 million, gaining access to a clinical phase I trispecific antibody in ophthalmology.
Strategic Investments & Minority Stakes
Roche holds several key strategic minority stakes and collaboration-driven investments:
- Freenome Holdings, Inc. (South San Francisco, United States): At 31 December 2025, Roche held a 15.90% equity interest in Freenome, an associate company accounted for using the equity method. Roche invested USD 50 million in January 2024 and an additional USD 75 million in November 2025 alongside a multi-year diagnostic out-licensing agreement for early cancer screening tests. The carrying value of Freenome stood at CHF 258 million.
- Zealand Pharma Collaboration: Entered an exclusive global partnership with Zealand Pharma to co-develop and co-commercialise petrelintide for obesity, combining clinical assets with Roche’s incretin pipeline candidate CT-388.
- Strategic Equity Holdings at Fair Value through OCI: Carried non-current equity stakes valued at CHF 78 million in private biotechnology entities, held to support strategic drug discovery alliances.
5. Power & Control: Roche Holding Executive Leadership & Ownership
The Brain Trust: Board of Directors & Executive Leadership
Corporate governance is maintained across the Board of Directors, which sets strategy and conducts corporate oversight, and the Corporate Executive Committee, which manages day-to-day operations:
Corporate Executive Committee:
- Thomas Schinecker (Chief Executive Officer, Roche Group): Leads the Corporate Executive Committee. Appointed CEO in 2023, having previously served as CEO of the Diagnostics Division.
- Teresa Graham (Chief Executive Officer, Roche Pharmaceuticals): Leads commercial and clinical operations across the Pharmaceuticals Division. Appointed to the executive committee in 2023.
- Matt Sause (Chief Executive Officer, Roche Diagnostics): Manages international commercial operations, instrumentation manufacturing, and assay R&D across the Diagnostics Division.
- Alan Hippe (Chief Financial Officer): Manages Group treasury, accounting, tax, corporate finance, and risk management functions.
- Cristina A. Wilbur (Chief People Officer): Leads international human resources, workforce health, safety, and organizational design.
- Claudia Böckstiegel (General Counsel): Member of the Enlarged Corporate Executive Committee leading legal affairs, corporate compliance, and intellectual property.
- Levi Garraway (Head Global Product Development and Chief Medical Officer): Member of the Enlarged Corporate Executive Committee overseeing clinical trial design, therapeutic safety, and regulatory filings.
- Silke Hörnstein (Head Corporate Strategy and Sustainability): Member of the Enlarged Corporate Executive Committee directing long-term portfolio planning and sustainability governance.
- Wafaa Mamilli (Chief Digital and Technology Officer): Member of the Enlarged Corporate Executive Committee overseeing enterprise informatics, cybersecurity, and digital health technology platforms.
- Aviv Regev (Head Genentech Research and Early Development): Member of the Enlarged Corporate Executive Committee directing discovery research and translational biology across Genentech.
- Barbara Schädler (Head Group Communications): Member of the Enlarged Corporate Executive Committee managing international public affairs, media, and brand identity.
- Boris Zaïtra (Head Corporate Business Development): Member of the Enlarged Corporate Executive Committee leading corporate M&A, out-licensing, in-licensing, and strategic venture investments.
Independent Board of Directors:
The Board of Directors is chaired by Severin Schwan. Board oversight is supported by independent non-executive directors including Vice-Chairman André Hoffmann, Jörg Duschmalé (representing the shareholder pooling group), Patrick Frost (Audit Committee Chair), Anita Hauser, Akiko Iwasaki, Richard P. Lifton, Jemilah Mahmood, Mark Schneider, and Claudia Suessmuth Dyckerhoff.
Who Owns the Stock?
Roche Holding Ltd maintains a dual-component capital structure consisting of voting bearer shares and non-voting equity securities (Genussscheine):
- Shareholder Pooling Group: At 31 December 2025, a shareholder group with pooled voting rights owned 69,318,000 bearer shares, representing 64.97% of the total issued voting share capital. This syndicate includes André Hoffmann, Marie-Anne Hoffmann, Vera Michalski, Alexander Hoffmann, Frederic Hoffmann, Isabel Hoffmann, Lucas Hoffmann, Marina Hoffmann, Kasia Barbotin-Larrieu, Tatiana Fabre, Andreas Oeri, Catherine Oeri, Sabine Duschmalé, Jörg Duschmalé, Lukas Duschmalé, the Wolf Foundation, and Artuma Holding LLC.
- Independent Founder Family Holders: Maja Oeri held 4,045,950 bearer shares (3.79% of issued shares) independently of the pool. Melchior Oeri similarly held 4,045,950 bearer shares (3.79% of issued shares) independently of the pool.
- Non-Voting Equity Securities (Genussscheine): A total of 702,562,700 non-voting securities are in issue, conferring identical rights to dividends and liquidation proceeds as the bearer shares, but carrying no voting participation.
- Capital Modernisation Proposal (2026 AGM): The Board has proposed modernising the capital structure by exchanging each non-voting equity security (Genussschein) for a participation certificate with a nominal value of CHF 0.001, alongside reducing the nominal value of bearer shares from CHF 1.00 to CHF 0.001 through a cash repayment of CHF 0.999 per share.
6. Strategic Outlook: Roche Holding Growth Catalysts & Key Risks
Competitive Advantages & Economic Moats
Roche maintains competitive positions in the life sciences sector supported by several operational factors:
- Dual Diagnostic-Therapeutic Integration: Combining in vitro diagnostic systems with targeted pharmaceutical pipelines enables the Group to co-develop companion diagnostics alongside new molecular entities, improving clinical trial stratification and therapy selection.
- Automated Laboratory Moats: With more than 31 billion diagnostic tests delivered in 2025 and thousands of cobas pro and cobas pure units placed in central hospital laboratories, high customer switching costs and multi-year supply contracts secure recurring reagent revenue.
- Specialized Biological Scale: Intellectual property portfolios, advanced protein engineering capabilities at Chugai, and commercial manufacturing facilities at Genentech and Mannheim create barriers to entry for biosimilar competitors.
- Subcutaneous Formulations: Proprietary subcutaneous administration delivery for established blockbusters (such as Phesgo replacing IV Perjeta/Herceptin and subcutaneous Ocrevus) extends clinical utility and therapy duration.
What Could Go Wrong? Key Challenges & Business Risks
The Group operates in a regulated and competitive international environment, subject to specific business and regulatory risks:
- Government Pricing Reforms and Mandatory Reductions: Exposure to mandatory public pricing reductions, such as the 340B Drug Discount Program and Medicaid in the US, reduced gross pharmaceutical billings by CHF 5,666 million in 2025. In China, volume-based procurement pricing policies have reduced revenues across Core Lab oncology, cardiac, and thyroid tests.
- Loss of Exclusivity and Biosimilar Erosion: Patent expirations on legacy products—including Avastin, Herceptin, MabThera, Actemra, Esbriet, and Lucentis—resulted in a combined sales erosion of CHF 0.7 billion at constant exchange rates during 2025. Perjeta patents expired in the US and Europe in 2025, and initial biosimilar entries are anticipated in 2026.
- Clinical Attrition and R&D Failure: High-risk clinical projects can encounter endpoints misses, such as the phase III ARNASA trial for astegolimab in respiratory disease, leading to product impairments.
- Currency Translation Volatility: Because Roche reports its consolidated financial statements in Swiss francs while generating the majority of its revenues in US dollars, euros, and Japanese yen, the appreciation of the Swiss franc had a negative net impact of 5 percentage points on reported sales and 8 percentage points on operating profit in 2025.
- Wholesale Customer Concentration: Approximately one-third of consolidated Group sales depend on three US pharmaceutical wholesalers—McKesson Corp., Cencora, Inc., and Cardinal Health, Inc.—exposing the Group to credit and supply channel risks.
The Next Chapter: Growth & Expansion Initiatives
The Group’s forward-looking strategic pipeline focuses on prioritized therapeutic areas addressing high disease burdens:
- Cardiovascular, Renal & Metabolism Expansion: Leveraging the acquisitions of Carmot Therapeutics and 89bio, Roche is advancing phase III pegozafermin for MASH and developing dual GLP-1/GIP receptor agonists (CT-388, CT-996, and CT-868), complemented by the Zealand Pharma alliance for petrelintide.
- Neuroscience Clinical Milestones: Fenebrutinib is progressing toward potential registration as an oral treatment for both relapsing and primary progressive multiple sclerosis, following positive pivotal phase III FENhance 2 read-outs. In Alzheimer’s disease, trontinemab showed reductions of amyloid plaques using Brainshuttle transport technology in phase Ib/IIa.
- Advanced Cancer Franchises: Broadening breast cancer treatment with Itovebi, which achieved EU approval for PIK3CA-mutant advanced breast cancer, while preparing for regulatory filings for giredestrant following positive pivotal evERA and lidERA phase III trial results in early and advanced ER-positive breast cancer.
- Novel Antibiotic Horizons: Advancing zosurabalpin into phase III clinical development, targeting difficult-to-treat gram-negative bacterial infections to address antimicrobial resistance.
- Sequencing and Diagnostic Commercialisation: Rolling out next-generation Sequencing by Expansion (SBX) instruments and commercializing the Elecsys pTau181 blood-based Alzheimer’s disease diagnostic assay to support early detection across healthcare networks.
The Verdict: Strategic Outlook & Conclusion
Roche concluded 2025 having delivered 7% constant currency sales expansion, 13% core operating profit growth, and 10 new molecular candidates into phase III development. The Group addressed biosimilar erosion across legacy biologics through the uptake of newer treatments such as Vabysmo, Ocrevus, Phesgo, and Hemlibra. While currency headwinds from the strong Swiss franc and mandatory healthcare pricing constraints in the US and China continue to affect reported numbers, the Group’s operational cash generation of CHF 18,852 million supports ongoing R&D reinvestment. Backed by its stable founding family ownership structure, Roche continues to execute against its long-term strategy of delivering targeted therapies and precision diagnostics to patients worldwide.
❓ Frequently Asked Questions: Roche Holding Ltd
What was Roche Holding Ltd’s revenue and net income in FY 2025?
In FY 2025, Roche Holding Ltd (SIX: ROG) reported total revenue of CHF 63.36 B (▲ 1.5% compared to CHF 62.40 B in the prior fiscal year). Gross profit stood at CHF 46.71 B (gross margin of 73.73 %). Operating profit was CHF 18.48 B and bottom-line net income was CHF 13.80 B.
Is Roche Holding Ltd profitable and generating positive cash flow in FY 2025?
Yes, Roche Holding Ltd was profitable in FY 2025, recording net profit of CHF 13.80 B (PAT margin: 21.78 %). On a cash basis, the company generated CHF 18.85 B in cash flow from operating activities and invested CHF 3.75 B in capital expenditures, resulting in free cash flow of CHF 15.10 B. Return on Equity (ROE) was 36.43 % and Cash ROE was 49.77 %.
How much debt, assets, and equity does Roche Holding Ltd hold?
As of FY 2025, Roche Holding Ltd held CHF 100.70 B in total assets, CHF 62.82 B in total liabilities, and CHF 37.88 B in total stockholders’ equity. Total debt stood at CHF 31.64 B (debt-to-equity ratio of 0.84x). Net working capital was CHF 10.73 B with a current ratio of 1.38x.
Who is the CEO and CFO of Roche Holding Ltd?
The Chief Executive Officer (CEO) of Roche Holding Ltd is Thomas Schinecker. The Chief Financial Officer (CFO) is Alan Hippe.
Where is Roche Holding Ltd headquartered and when was it founded?
Roche Holding Ltd is headquartered in Grenzacherstrasse 124, 4070 Basel, Switzerland. The company traces its founding/incorporation to 1896. Total disclosed workforce/headcount is 112,774. Its official corporate website is https://www.roche.com.
Note: Financial ratios, margins, year-over-year (YoY) growth rates, and percentage shares of revenue are calculated by FirmsWorld based on figures reported in the company’s official annual report.